107 related articles for article (PubMed ID: 1826961)
1. Clinical trials with etanidazole (SR-2508) by the Radiation Therapy Oncology Group (RTOG).
Wasserman TH; Lee DJ; Cosmatos D; Coleman N; Phillips T; Davis L; Marcial V; Stetz J
Radiother Oncol; 1991; 20 Suppl 1():129-35. PubMed ID: 1826961
[TBL] [Abstract][Full Text] [Related]
2. Progress report of a phase II and a phase III trial with etanidazole (SR-2508): a multicentre European study.
Chassagne D; Sancho-Garnier H; Charreau I; Eschwege F; Malaise EP
Radiother Oncol; 1991; 20 Suppl 1():121-7. PubMed ID: 1826960
[TBL] [Abstract][Full Text] [Related]
3. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas.
Lee DJ; Cosmatos D; Marcial VA; Fu KK; Rotman M; Cooper JS; Ortiz HG; Beitler JJ; Abrams RA; Curran WJ
Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):567-76. PubMed ID: 7790241
[TBL] [Abstract][Full Text] [Related]
4. Logistics in designing clinical trials for etanidazole (SR 2508): an RTOG experience.
Lee DJ; Phillips TL; Coleman CN; Cosmatos D; Davis LW; Wasserman TH; Marcial VA; Rubin P
Int J Radiat Oncol Biol Phys; 1992; 22(3):569-71. PubMed ID: 1531215
[TBL] [Abstract][Full Text] [Related]
5. First analysis of tumor regression for the European randomized trial of etanidazole combined with radiotherapy in head and neck carcinomas.
Chassagne D; Charreau I; Sancho-Garnier H; Eschwege F; Malaise EP
Int J Radiat Oncol Biol Phys; 1992; 22(3):581-4. PubMed ID: 1531218
[TBL] [Abstract][Full Text] [Related]
6. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27.
Lee WR; Berkey B; Marcial V; Fu KK; Cooper JS; Vikram B; Coia LR; Rotman M; Ortiz H
Int J Radiat Oncol Biol Phys; 1998 Dec; 42(5):1069-75. PubMed ID: 9869231
[TBL] [Abstract][Full Text] [Related]
7. Final report of the phase I trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) Radiation Therapy Oncology Group 83-03.
Coleman CN; Wasserman TH; Urtasun RC; Halsey J; Noll L; Hancock S; Phillips TL
Int J Radiat Oncol Biol Phys; 1990 Feb; 18(2):389-93. PubMed ID: 2154420
[TBL] [Abstract][Full Text] [Related]
8. A phase I/II study of the hypoxic cell sensitizer misonidazole as an adjunct to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: a RTOG randomized study (#79-04).
Lee DJ; Pajak TF; Stetz J; Order SE; Weissberg JB; Fischer JJ
Int J Radiat Oncol Biol Phys; 1989 Feb; 16(2):465-70. PubMed ID: 2646255
[TBL] [Abstract][Full Text] [Related]
9. Results of a European randomized trial of Etanidazole combined with radiotherapy in head and neck carcinomas.
Eschwège F; Sancho-Garnier H; Chassagne D; Brisgand D; Guerra M; Malaise EP; Bey P; Busutti L; Cionini L; N'Guyen T; Romanini A; Chavaudra J; Hill C
Int J Radiat Oncol Biol Phys; 1997 Sep; 39(2):275-81. PubMed ID: 9308928
[TBL] [Abstract][Full Text] [Related]
10. Final report of the phase I trial of continuous infusion etanidazole (SR 2508): a Radiation Therapy Oncology Group study.
Coleman CN; Noll L; Riese N; Buswell L; Howes AE; Loeffler JS; Alexander E; Wen P; Harris JR; Kramer RA
Int J Radiat Oncol Biol Phys; 1992; 22(3):577-80. PubMed ID: 1531217
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic monitoring and dose modification of etanidazole in the RTOG 85-27 phase III head and neck trial.
Riese NE; Buswell L; Noll L; Pajak TF; Stetz J; Lee DJ; Coleman CN
Int J Radiat Oncol Biol Phys; 1997 Nov; 39(4):855-8. PubMed ID: 9369134
[TBL] [Abstract][Full Text] [Related]
12. Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck.
Haffty BG; Son YH; Wilson LD; Papac R; Fischer D; Rockwell S; Sartorelli AC; Ross D; Sasaki CT; Fischer JJ
Radiat Oncol Investig; 1997; 5(5):235-45. PubMed ID: 9372546
[TBL] [Abstract][Full Text] [Related]
13. Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a Phase II study.
Lee DJ; Trotti A; Spencer S; Rostock R; Fisher C; von Roemeling R; Harvey E; Groves E
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):811-5. PubMed ID: 9845102
[TBL] [Abstract][Full Text] [Related]
14. The multi-dose clinical tolerance and pharmacokinetics of the combined radiosensitizers, Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
Newman HF; Ward R; Workman P; Bleehen NM
Int J Radiat Oncol Biol Phys; 1988 Nov; 15(5):1073-83. PubMed ID: 2972667
[TBL] [Abstract][Full Text] [Related]
15. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
[TBL] [Abstract][Full Text] [Related]
16. The combination of multiple doses of etanidazole and pimonidazole in 48 patients: a toxicity and pharmacokinetic study.
Bleehen NM; Maughan TS; Workman P; Newman HF; Stenning S; Ward R
Radiother Oncol; 1991; 20 Suppl 1():137-42. PubMed ID: 1826962
[TBL] [Abstract][Full Text] [Related]
17. Intervention with the hypoxic tumor cell sensitizer etanidazole in the combined modality treatment of limited stage small-cell lung cancer. A one-institution study.
Urtasun RC; Palmer M; Kinney B; Belch A; Hewitt J; Hanson J
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(2):337-42. PubMed ID: 9457818
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of pharmacokinetic monitoring and dose modification of etanidazole on the incidence of neurotoxicity: results from a phase II trial of etanidazole and radiation therapy in locally advanced prostate cancer.
Coleman CN; Buswell L; Noll L; Riese N; Rose MA
Int J Radiat Oncol Biol Phys; 1992; 22(3):565-8. PubMed ID: 1310497
[TBL] [Abstract][Full Text] [Related]
19. Abnormal clinical pharmacokinetics of the developmental radiosensitizers pimonidazole (Ro 03-8799) and etanidazole (SR 2508).
Maughan TS; Newman HF; Bleehen NM; Ward R; Workman P
Int J Radiat Oncol Biol Phys; 1990 May; 18(5):1151-6. PubMed ID: 2140825
[TBL] [Abstract][Full Text] [Related]
20. A multiple dose study of the combined radiosensitizers Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
Bleehen NM; Newman HF; Maughan TS; Workman P
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1093-6. PubMed ID: 2539346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]